CP 1644 BOXSEQ **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Hon. Commission of By Denise M. Squires (print name)

LUD 5253.5 DIV-JEL/NDH (09885911)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants** 

Thierry BOON-FALLEUR et al.

Serial No.

08/819,669

Filed

March 17, 1997

For

TUMOR, REJECTION, ANTIGEN PRECURSORS, TUMOR

REJECTION ANTIGENS AND USES THEREOF

Art Unit

1644

Examiner

T. Cunningham

Hon. Commissioner of Patents

September 23, 1999

and Trademarks

**BOX AF** 

Washington, D.C. 20231

## **LETTER**

SIR:

In response to the Notice of August 31, transmitted herewith is a new CRF and paper copy of sequence information presented therein. It is asked that these materials be used to REPLACE the current CRF and paper copy of same.

LUD 5253.5 DIV-JEL/NDH (09885911)

It is noted that the action of May 7, 1999 did <u>NOT</u> include the points raised herein, although it was a sequence compliance letter. It is believed that the examiner is unduly prolonging prosecution.

The undersigned hereby asserts that to the best of his knowledge, the attached CRF and accompanying paper copy of same present information that is identical to each other and to information in the application as filed. No new matter is believed presented.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L. L.P.

3y: 1000

Norman D. Hanson

Reg. No. 30,946

666 Fifth Avenue New York, New York 10103

Direct Line: 212-318-3168

General Number: 212-318-3000

NOTICE TO COMPLE WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

| The  | nucleotide | and/or    | amino   | acid      | Беф | Menor | W | sclosur  | cont  | ained | l in th | ıis | app | lica | tion  | doc |
|------|------------|-----------|---------|-----------|-----|-------|---|----------|-------|-------|---------|-----|-----|------|-------|-----|
| not  | compra arc | n the re  | equire: | nents     | tor | such  | а | disclos: | re as | set   | forth   | in  | 37  | CFR  | 1.821 | 406 |
| 1.82 | 25 for the | tollowing | ng reas | 30n ( 8 ) | :   |       |   |          |       |       |         |     |     |      |       | •   |

| 1. This application clearly fails to comply with the requirements of 37 CFR 1.8   |
|---|
| - 1.825. Applicant's attention is directed to these regulations, published at 1114 og May 15, 1990 and at 55 FR 18230, May 1, 1990. SEE ATTACHED SHEET  |
| 2. This application does not contain, as a separate part of the disclosure on   |
| paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).  |
| 3. A copy of the "Sequence Listing" in computer readable form has not been  |
| submitted as required by 37 CFR 1.821(e).   |
| 4. A copy of the "Sequence Listing" in computer readable form has been submitte   |
| However, the content of the computer readable form does not comply with the requiremen of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." |
| 5. The computer readable form that has been filed with this application has bee   |
| found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).           |
| 6. The paper copy of the "Sequence Listing" is not the same as the computer   |
| readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).   |
|   |
| Other:  |
| Applicant must provide:   |
| An initial or substitute computer readable form (CRF) copy of the "Sequence   |
| Listing"  |
| An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification   |
| A statement that the content of the paper and computer readable copies are the s  |

and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please conta

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400